

VASCADE®



We Stand Behind
Our Performance

Guaranteed

SHARING RISK BY SHARING COSTS

In Performance Guarantee Accounts:

partially
OFFSETS
YOUR COSTS
of complications

<1 IN 1,000
complications*

EASY
to implement

* In Performance Guarantee accounts from Q3 2016 through Q1 2018. Definition of complications listed in contractual agreements.

ORDERING INFORMATION:

Product	Model Number	Description	Order Quantity
VASCADE 5F VCS	700-500DX-05U	5 French	1 Box (5 Devices/Box)
VASCADE 6/7F VCS	700-580I-05U	6/7 French	1 Box (5 Devices/Box)

The VASCADE® Vascular Closure System (VCS) is indicated for femoral arterial or femoral venous access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a 5F, 6F, or 7F procedural sheath.

The VASCADE VCS is also indicated to reduce time to discharge eligibility when used for femoral arterial closure in patients who have undergone diagnostic endovascular procedures using a 5F, 6F, or 7F procedural sheath.

CONTRAINDICATIONS: The VASCADE VCS should not be used in patients with a known allergy to bovine derivatives.

Before use, physicians should review all risk information, which can be found in the "Instructions for Use."

Founded in July 2002, CARDIVA Medical, Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technologies designed to help the body heal itself.

CARDIVA
MEDICAL, INC.

1615 Wyatt Drive, Santa Clara, CA 95054
P: 866.602.6099 F: 866.602.1795
customerservice@cardivamedical.com
www.CardivaMedical.com

2019© Cardiva Medical, Inc.
VASCADE is a registered trademark of Cardiva Medical, Inc.

LIT 3575 Rev D

VASCADE[®]

ARTERIAL & VENOUS CLOSURE

Now
Indicated for
FEMORAL VEINS

Safe. Simple. Guaranteed.

- Better Clinical Outcomes
- Improving Patient Satisfaction



CARDIVA
MEDICAL, INC.

www.cardivamedical.com

THE ONLY closure device proven safer than manual compression in a randomized clinical trial¹

ZERO major complications¹


up to **4x** **FASTER** to hemostasis¹

up to **1.5x** **FASTER** to ambulation¹

Safe


RAPID HEMOSTASIS FOR INTERVENTIONAL AND DIAGNOSTIC PROCEDURES

RESPECT – Level 1 Evidence: Prospective, Multi-Center Randomized Clinical Trial²




** Data for the chart is from U.S. FDA SSED and IFU's and includes both Interventional and Diagnostic treatment arms. All ITT patients and events are included in the chart.

TIME TO HEMOSTASIS² P<0.0001



TIME TO AMBULATION² P<0.0001




Interventional and Diagnostic Cases

1. IFU's and/or SSED's of commercially available leading brands (VASCADE, AngioSeal, Mynx, Perclose, Starclose, Exoseal).


2. Hermiller JB, et al. A Prospective, Randomized, Pivotal Trial of a Novel Extravascular Collagen-Based Closure Device Compared to Manual Compression in Diagnostic and Interventional Patients *Journal of Invasive Cardiology* 2015;27(3):129-136

Simple


ELEGANTLY SIMPLE, MECHANICAL AND PHYSIOLOGICAL HEMOSTASIS



Exchange sheath for VASCADE and verify disc location



Release collagen patch



Remove VASCADE and obtain hemostasis

2 mechanisms of action
mechanical and physiological

>1/2 MILLION
discs sold³

~13X expansion of
collagen patch⁴

SIMPLE design

BIOABSORBABLE
collagen

utilizes existing
PROCEDURAL
SHEATH

RAPID
HEMOSTASIS
in heparinized blood⁴

EXTRAVASCULAR



³ Includes all Cardiva Medical products sold as of May 2017

⁴ Data on file at Cardiva Medical